While the Aduhelm controversy received extensive media coverage, McKinsey’s behind-the-scenes role in promoting the drug has remained hidden from the public. Documents obtained in connection with the reporting of this book show McKinsey’s strong support for the Alzheimer’s drug. In April 2021, months after the FDA’s expert panel questioned the efficacy of Aduhelm, Kevin Sneader, then McKinsey’s managing partner, praised the drug, calling it a “first-in-class disease-modifying therapy for Alzheimer’s.” For that reason, he said, Biogen expected “massive public interest in the drug and the
...more
